Skip to main content
logo
Bausch + Lomb Corporation (BLCO)
NYSE: BLCO · Real-Time Price · USD
17.22
+0.16 (0.94%)
At close: Mar 9, 2026, 4:00 PM EDT
17.20
-0.02 (-0.12%)
After-hours: Mar 9, 2026, 7:00 PM EDT

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
U.S. and Puerto Rico Revenue
2.55B2.41B
U.S. and Puerto Rico Revenue Growth
5.51%24.77%
Total International Revenue
2.56B2.38B
Total International Revenue Growth
7.44%7.51%
Revenue (Total)
5.10B4.79B
Revenue (Total) Growth
6.47%15.56%

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Vision Care Revenue
2.92B2.74B
Vision Care Revenue Growth
6.72%7.71%
Surgical Revenue
894.00M843.00M
Surgical Revenue Growth
6.05%9.91%
Ophthalmic Pharmaceuticals Revenue
1.28B1.21B
Ophthalmic Pharmaceuticals Revenue Growth
6.20%44.62%
Revenue (Other)
--
Revenue (Total)
5.10B4.79B
Revenue (Total) Growth
6.47%15.56%

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Pharmaceuticals Revenue
1.08B969.00M
Pharmaceuticals Revenue Growth
11.56%56.80%
Devices Revenue
1.92B1.80B
Devices Revenue Growth
6.78%9.09%
OTC Revenue
1.83B1.72B
OTC Revenue Growth
6.38%7.01%
Branded and Other Generics Revenue
243.00M281.00M
Branded and Other Generics Revenue Growth
-13.52%11.51%
Total Product Revenue
5.08B4.77B
Total Product Revenue Growth
6.41%15.57%
Other Product Revenue
21.00M17.00M
Other Product Revenue Growth
23.53%13.33%
Revenue (Total)
5.10B4.79B
Revenue (Total) Growth
6.47%15.56%

EBIT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Vision Care Segment Profit
849.00M808.00M
Vision Care Segment Profit Growth
5.07%17.27%
Surgical Segment Profit
18.00M44.00M
Surgical Segment Profit Growth
-59.09%-12.00%
Ophthalmic Pharmaceuticals Segment Profit
258.00M256.00M
Ophthalmic Pharmaceuticals Segment Profit Growth
0.78%6.22%
Corporate Segment Profit
-679.00M-614.00M
Amortization of Intangible Assets
-258.00M-288.00M
Net Other Expense
-75.00M-44.00M
Operating Income (Other)
--
Operating Income (Total)
113.00M162.00M
Operating Income (Total) Growth
-30.25%24.62%

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Vision Care Revenue Change in Constant Currency
5.00%10.00%
Surgical Revenue Change in Constant Currency
6.00%11.00%
Ophthalmic Pharmaceuticals Revenue Change in Constant Currency
4.00%45.00%
Total Revenue Change in Constant Currency
6.00%17.00%
Updated Feb 18, 2026. Data Source: Fiscal.ai.